Pazan, Farhad
Petrovic, Mirko
Cherubini, Antonio
Onder, Graziano
Cruz-Jentoft, Alfonso J.
Denkinger, Michael
van der Cammen, Tischa J. M.
Stevenson, Jennifer M.
Ibrahim, Kinda
Rajkumar, Chakravarthi
Bakken, Marit Stordal
Baeyens, Jean-Pierre
Crome, Peter
Frühwald, Thomas
Gallaghar, Paul
Guðmundsson, Adalsteinn
Knol, Wilma
O’Mahony, Denis
Pilotto, Alberto
Rönnemaa, Elina
Serra-Rexach, José Antonio
Soulis, George
van Marum, Rob J.
Ziere, Gijsbertus
Mair, Alpana
Burkhardt, Heinrich
Neumann-Podczaska, Agnieszka
Wieczorowska-Tobis, Katarzyna
Fernandes, Marilia Andreia
Gruner, Heidi
Dallmeier, Dhayana
Beuscart, Jean-Baptiste
van der Velde, Nathalie
Wehling, Martin https://orcid.org/0000-0003-1393-1691
Article History
Received: 24 March 2020
Accepted: 30 June 2020
First Online: 7 August 2020
Change Date: 7 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00228-021-03166-1
Compliance with ethical standards
:
: MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (=translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire, and LEO Pharma. AC received lecturing and consulting fees from Bristol Myers Squibb, Nestle and MSD. MD has received lecturing and consulting fees from Daiichi-Sankyo and Novartis. FP, MP, AG, ANP, DOM, GZ, HB, JBB, JMS, KI, MAF, MSB, NVDV, PC, CR, JASR, TF, TVDC, ACJ, GO, RJVM, WK, KWT, PG, GS, JPB, DD, HG, AP, AM, and ER declare that they have no conflict of interest.